SNIBE(SZ:300832) Zheng Quan Ri Bao Zhi Sheng·2026-01-07 13:49Core Insights - The company is focusing on expanding its presence in tertiary hospitals, which account for over half of hospital visits and are key end-users of in vitro diagnostic products [1] - The company plans to enhance its product offerings with cost-effective solutions like MAGLUMI X3 and MAGLUMI X6 to cater to secondary and lower-tier medical markets [1] - The company aims to increase its market share in both domestic and international immunodiagnostic markets, which currently remain relatively low, indicating significant growth potential [1] Domestic Market Strategy - The company is increasing efforts to penetrate tertiary hospitals with its high-speed luminescent instruments MAGLUMI X8, MAGLUMI X10, and SATLARS T8 [1] - The focus is on improving single-machine output while also addressing the needs of smaller medical facilities through affordable product development [1] International Market Strategy - The company is witnessing a rise in sales of mid-to-large machines in overseas markets, with the proportion increasing from 57% in 2023 to 76% in the first three quarters of 2025 [1] - The strategy includes a stronger emphasis on expanding large machines and production lines in high-end global markets to drive growth from large sample volume clients [1]